Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
Idiopathic pulmonary fibrosis (IPF) is the most common form of chronic idiopathic diffuse interstitial lung disease (DILD) in adults. It is a fibroproliferative, irreversible disease of unknown cause, usually progressive, occurring mainly from the age of 60 and limited to the lungs. IPF is a serious disease with a median survival rate at diagnosis of 3 years.
The aim of the study is to set up a biocollection of serum from patients in a context of idiopathic DILD and a possible or confirmed diagnosis of common interstitial lung disease by chest CT.
Patients will be recruited at the consultations of the Rennes Rare Lung Disease Competence Centre. These will be patients in stable condition or in acute exacerbation of IPF.
Full description
This study will initially focus on circulating serum CD163 markers, but a broader proteomics approach could be considered in a second phase to look for other markers of lung diseases.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
903 participants in 1 patient group
Loading...
Central trial contact
Stéphane JOUNEAU, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal